102 results about "Neutrophile" patented technology

The invention provides a biomarker for diagnosing systemic lupus erythematosus and application of the biomarker. According to the application disclosed by the invention, the expression of Ferritin in neutrophil of a systemic lupus erythematosus patient is found to be obviously reduced and is improved after treatment, the neutrophil has disease specificity and cell specificity, and the Ferritin in the neutrophil has important significance on clinical diagnosis or auxiliary diagnosis of systemic lupus erythematosus and disease condition evaluation.

The invention discloses a systemic lupus erythematosus molecular diagnosis marker based on neutrophil characteristics. The invention provides application of a substance for detecting the expression quantity of an IFIH1 gene and / or a CFLAR gene in preparation of a product for auxiliary diagnosis or screening or auxiliary screening of systemic lupus erythematosus. The invention also provides an application of a substance for detecting the relative expression quantity of the IFIH1 gene and the CFLAR gene and a carrier loaded with the following combined index C value model formula in preparation of a product for auxiliary diagnosis or screening or auxiliary screening of systemic lupus erythematosus. The specific gene expression marker IFIH1 and / or CFLAR of the neutrophile granulocyte is selected by focusing the unique change of the SLE neutrophile granulocyte to assist the clinical early-stage identification and diagnosis of the SLE, and an IFIH1 and CFLAR combined diagnosis model is constructed, so that the diagnosis or screening of the SLE is realized; the kit has high sensitivity and specificity.

The invention relates to the technical field of plant extracts, and provides a plant extract composition with synergistic hypoglycemic activity and application thereof, and the plant extract composition comprises a mulberry leaf extract, a white kidney bean extract and bitter gourd powder in a mass ratio of 8: (1-24): (1-64). By optimizing the mass ratio of the mulberry leaf extract, the white kidney bean extract and the bitter gourd powder, the blood sugar reducing effect of the plant extract taking the mulberry leaf extract, the white kidney bean extract and the bitter gourd powder as main raw materials is remarkably superior to that of a plant extract in the prior art. Meanwhile, the plant extract composition also has the effects of synergistically reducing the number of neutrophils around nerves, improving peripheral neuroinflammation, synergistically enhancing the fluorescence intensity of the peripheral nerves, improving peripheral nerve injury and inhibiting the enzymatic activity of a bacterium source dipeptidyl peptidase-4.

The present invention relates to the field of medical testing technology, and in particular to a method for rapidly detecting neutrophil extracellular traps. The method comprises the following steps: (1) taking a human whole blood sample, adding a hemolytic agent, and then adding a mixed fluorescent antibody staining solution, shaking and mixing, and incubating at room temperature; (2) centrifuging after incubation in step (1), discarding the supernatant, washing with a washing solution, and then centrifuging, discarding the supernatant; (3) adding a washing solution to resuspend the cells; (4) using a flow cytometer for detection. The detection method has good stability, strong repeatability, and high fluorescence intensity, and can be used for auxiliary diagnosis of diseases.

The features of the present invention for providing a novel neutrophil activator are as follows. 1. An IL-8 production accelerator containing at least one selected from GlcCer[d18:2(4E,8Z) / 18:0], GlcCer[d18:2(4E,8Z) / 20:0], GlcCer[d18:2(4E,8Z) / 22:0], GlcCer[d18:2(4E,8Z) / 24:0], and GlcCer[d18:2(4E,8Z) / 26:0] as an active ingredient. 2. An IL-8 production accelerator containing GlcCer[d18:2(4E,8E) / 24:0] as an active ingredient. 3. An IL-8 production accelerator containing at least one selected from GlcCer[t18:1(8Z) / 24:0] and GlcCer[t18:1(8Z) / 26:0] as an active ingredient. 4. An IL-8 production accelerator containing GlcCer[d18:1(4E) / 20:0] as an active ingredient. 5. An IL-8 production accelerator containing at least one selected from Cer(t18:0 / 22:0), Cer(t18:0 / 23:0), Cer(t18:0 / 24:0), Cer(t18:0 / 25:0), and Cer(t18:0 / 26:0) as an active ingredient. 6. An IL-8 production accelerator containing at least one selected from Cer[t18:1(8Z) / 24:0] and Cer[d18:2(4E,8Z) / 20:0] as an active ingredient. 7. An IL-8 production accelerator containing at least one selected from Oryza Ceramide A, Oryza Ceramide B, and Oryza Ceramide C as an active ingredient.

Described herein are methods and compositions relating to methods of inhibiting neutrophils, e.g., inhibiting NET release or NETosis, by means of a DEspR inhibitor, e.g., an anti-DEspR antibody reagent. In some embodiments, the methods can relate to the treatment of a disease, e.g., cancer or a disease wherein neutrophils; NETs; or NETosing or NETting neutrophils contribute to pathogenesis, chronicity, or worsening of disease. In some embodiments, the DEspR inhibitor can be a bi-specific reagent or an antibody-drug conjugate.

A family of bioactive compounds identified in self-resolving inflammatory exudates is disclosed. The compounds give UV chromophores characteristic of a conjugated triene double bond system coupled to an auxochrome allylic to the triene. Further elucidation of the compounds reveals that they have a resolvin backbone conjugated to a peptide or amino acid moiety via an auxochrome. In some embodiments the auxochrome is sulfur. However, the auxochrome may be NH, CH2 or O. The compounds have potent bioactivity, in vitro, and, in vivo, including promoting resolution of infection, stimulating macrophage phagocytosis of bacteria; protecting tissues from neutrophil mediated damage, promoting tissue repair and regeneration and preventing or limiting second organ reflow / reperfusion damage.

The present application relates to the field of biological medicine, in particular to a sensitizing agent for constructing a neutrophilic asthma animal model, a construction method and application. The present application uses Haemophilus influenzae outer membrane vesicles and ovalbumin as a sensitizing agent to construct a neutrophilic asthma animal model, and the test results show that the level of neutrophils in the blood and lung lavage fluid of mice is significantly increased compared with the treatment of ovalbumin as a sensitizing agent alone. The constructed mouse neutrophilic asthma model can be used for the research on the mechanism of clinical neutrophilic asthma and the development of neutrophilic asthma drugs.

The application belongs to the technical field of medicine, and specifically discloses a kind of nasal spray composition and nasal spray and application, the nasal spray composition includes the following components: hyaluronic acid, trehalose, N-acetyl-L-cysteine, methylene succinic acid, gallic acid, taurine, coenzyme Q10, rosemary essential oil.The nasal spray composition provided by the application is accurately adjusted, can give full play to the advantages of each component, provide better nasal ventilation and humidity.The nasal spray composition provided by the application can inhibit the excessive activation of LPS-induced neutrophil Netosis in vitro culture and the excessive activation of LPS-induced mouse airway neutrophil Netosis, thereby reducing the inflammatory response in the nasal cavity.

The application provides a culture method and composition for prolonging the in-vitro survival time of neutrophils. The composition provided by the application comprises prednisolone and beta-mercaptoethanol, which can prolong the survival time of neutrophils. The method provided by the application has low cost, simple operation, small interference to cell function, can guarantee an experimental window of 3-4 days, and has good application value.

The invention relates to the technical field of biological medicine preparations, in particular to application of targeted nanoparticles in treatment of osteoporosis. The targeted nano-particles CL-NPs (at) NEs are developed, CL can stimulate lipolysis of bone marrow adipocytes, osteogenic differentiation is promoted, and therefore the bone marrow microenvironment is improved; meanwhile, autologous neutrophil is used as a carrier to transport CL-NPs, bone marrow fat cells beta3AR are accurately targeted, and the osteoporosis microenvironment can be further improved. Experiments prove that CL-NPs (at) NEs stimulate a bone marrow fat cell beta3 adrenoceptor in a targeted manner, can effectively improve OP, has safety and has the potential to become a novel medicine for osteoporosis.

The invention discloses a novel nuclear magnetic resonance contrast agent Gd-DOTA-PP for targeting citrullinated histone to achieve neutrophil extracellular trap net imaging and a preparation method and application thereof.The method comprises the steps that citrullinated histone targeting polypeptide PP and ligand molecules DOTA-NHS are combined, and a compound DOTA-PP is obtained; and then gadolinium (Gd) ions are introduced into the DOTA-PP through a coordination reaction, and the novel contrast agent Gd-DOTA-PP is prepared. The contrast agent can be selectively combined with an important marker, namely citrullinated histone, of neutrophil extracellular trapping nets (NETs), and T1 weighted imaging signals of a target area are remarkably enhanced. The preparation method is simple and convenient to operate, the preparation process is highly controllable, and the obtained contrast agent has excellent biocompatibility and targeting characteristic. The accurate targeting ability of the probe enables the influence signal of the probe in NETs enrichment areas such as tumor early metastasis, tumor infiltration lymph nodes and the like to be obviously enhanced, a powerful tool is provided for tumor diagnosis, especially accurate diagnosis of the early metastasis, and the probe has important clinical application value.

The invention relates to a fluorescent reagent for detecting human neutrophil apolipoprotein and application of the fluorescent reagent. The fluorescent reagent comprises a fluorescent reagent I and a fluorescent reagent II, the fluorescent reagent I and the fluorescent reagent II are encapsulated in polymethyl methacrylate microspheres and have single-excitation dual-emission characteristics, the excitation light is near 345 nm, the emission light is near 445 nm and 615 nm respectively, and the emission light of 615 nm is later than the emission light of 445 nm. The reagent, a buffer solution and human neutrophil apolipoprotein antibody protein form a detection kit, and the detection kit is used for detecting neutrophil apolipoprotein in fresh human venous blood. The preparation method comprises the steps of fluorescent microsphere preparation, antibody preparation, microsphere surface activation, coupling reaction, sealing, cleaning, storage and the like. The detection method comprises the following steps: taking serum, mixing the fluorescent microsphere compound, detecting a fluorescence value and calculating the protein concentration. The method improves the sensitivity and accuracy of a detection system, is simple and convenient to operate and short in time consumption, and has a wide application prospect.

The invention provides a method for extracting neutrophil extracellular traps based on ANXA2, and belongs to the technical field of cell component extraction. By utilizing the exogenous ANXA2 protein to stimulate or endogenously express the ANXA2 protein, not only is the survival rate of primary neutrophils not influenced, but also the generation of neutrophils extracellular traps (NETs) can be promoted. Therefore, compared with a traditional method (PMA extraction method), the method for extracting the NETs by stimulating the neutrophil on the basis of ANXA2 provided by the invention has the advantages that the NETs can be effectively extracted at low concentration (20-150nM), the cell survival rate is remarkably improved, and the extraction amount of the NETs is increased.

This invention discloses an antimicrobial peptide, its pharmaceutical composition, and its applications. The invention optimizes the structure of the antimicrobial peptide through deuteration modification technology, significantly enhancing its targeted binding ability to β-1,3-D-glucan synthase. The affinity of this antimicrobial peptide for the aforementioned target is 9-27 times that of the control peptide. In vitro assays show that its minimum inhibitory concentration (MIC) against nine standard Candida strains is consistently 0.002 μg / mL, exhibiting significantly superior activity compared to fluconazole, anidoxurine, and the control peptide. It also exhibits extremely low cytotoxicity against L02 human normal hepatocytes. In in vivo experiments, in a neutropenic mouse model of Candida albicans infection, the antimicrobial peptide at all doses showed superior reduction in renal fungal load compared to anidoxurine and the control peptide. The antimicrobial peptide of this invention combines highly efficient anti-Candida activity, low cytotoxicity, and excellent in vivo efficacy, providing a safe and effective candidate drug for the treatment of drug-resistant candidiasis and possessing good clinical translational value.

The invention provides methods of determining the neutrophil level in a sample by determining the level of CD16b, including the intracellular form of CD16b in a sample, such as a blood sample. The methods may further comprise the determination of lactate levels Also provided are associated diagnostic and therapeutic methods. Further provided are kits and devices for performing the methods, particularly lateral flow kits and devices.

The present disclosure provides a biomarker for accumulation of neutrophil extracellular traps (NETs) or extracellular chromatin. The present disclosure also provides methods for the treatment for inflammatory disease, including methods of predicting response to treatment, methods of patient selection for treatment, and determination of therapeutic dose.

Provided in the present invention is a method for preparing a drug-loaded neutrophil. The method comprises the step of co-incubating, in a buffer containing nicotinamide, Q-VD-Oph and vitamin C, a neutrophil and a drug to be loaded. Further provided in the present invention are a drug-loaded neutrophil prepared using the method, and the use of the neutrophil in the preparation of a drug. The method provided in the present invention can significantly reduce the apoptosis ratio of neutrophils, reduce the in-vitro activation level of neutrophils, improve neutrophil viability and chemotactic efficiency under inflammatory conditions, and also improve the drug-loading efficiency of neutrophils, thereby realizing the efficient release of a drug at a disease site, and further improving the in-vivo survival time and efficacy of the drug.

The invention discloses a construction method of a CAPN1 gene myeloid specific knockout mouse viral myocarditis animal model. The construction method comprises the following steps: carrying out gene identification on a mouse, distinguishing genotypes, extracting genome DNA (Deoxyribonucleic Acid), designing specific primers aiming at a CAPN1 gene and a Lyz2-Cre gene, carrying out PCR (Polymerase Chain Reaction) amplification, and carrying out gel electrophoresis detection on a PCR product; a PCR reaction system comprises extracted DNA, Taq polymerase and dNTPs, a CAPN1flox / flox mouse shows a normal fragment of the CAPN1 gene, a cKO mouse shows deletion of a specific region of the CAPN1 gene, a Lyz2-Cre + mouse shows a band of the Cre gene, and a CAPN1 gene myeloid specific knockout mouse is obtained. The construction of the viral myocarditis animal model by down-regulating the Calpain1 level in the neutrophile granulocyte has important application value.

This invention discloses an engineered attenuated Salmonella VNP-SNase, its preparation method, and its applications, including methods and compositions for treating various solid tumors or metastatic tumors. Specifically, engineered attenuated Salmonella capable of expressing and secreting SNase is recruited to the tumor microenvironment through tumor targeting, specifically degrading intratumoral neutrophil extracellular traps (NETs), weakening the killing effect of NETs on Salmonella, increasing its intratumoral colonization, and simultaneously improving the tumor-promoting and immunosuppressive effects caused by NETs, ​​while effectively preventing bacteria from off-target into normal organs. By releasing SNase to activate / regulate the immune system and directly / indirectly inhibit tumors, it can act as an effective immune effector.

The invention discloses application of a polygonatum odoratum polysaccharide extract in preparation of a medicine for treating viral pneumonia, and belongs to the technical field of medicines. Through experiments, the applicant discovers that the polygonatum odoratum polysaccharide extract can significantly reduce the fluorescence intensity of neutrophils and macrophages in poly (I: C) induced zebrafish viral pneumonia model swimming sacs, has an obvious antiviral effect on zebrafish, can reduce the expression of pro-inflammatory factors tnf alpha, il6 and il12, has an obvious anti-inflammatory effect, and can be used for preparing anti-inflammatory drugs for treating zebrafish viral pneumonia. The compound is expected to be used for preparing anti-viral pneumonia drugs.

The invention provides a neutrophil transporter, a marker CD66b of the neutrophil transporter, and application of combination of the CD66b and other indexes to early diagnosis or auxiliary diagnosis of blood coagulation disorder. The invention provides CD66b, application of CD66b and other index combinations to preparation of reagents or kits for early diagnosis or auxiliary diagnosis of blood coagulation disorders, related reagents and kits, and a system for early diagnosis or auxiliary diagnosis of blood coagulation disorders. The CD66b, the combination of the CD66b and other indexes, the reagent or the kit and the system provided by the invention have the effect of early diagnosis or auxiliary diagnosis of the blood coagulation disorder.

The present application relates to the technical field of plant extract, and provides a plant extract composition with synergistic hypoglycemic activity and application thereof, wherein the plant extract composition comprises mulberry leaf extract, white kidney bean extract and balsam pear powder with a mass ratio of 8:(1-24):(1-64). The present application optimizes the mass ratio of the mulberry leaf extract, the white kidney bean extract and the balsam pear powder, so that the plant extract with the mulberry leaf extract, the white kidney bean extract and the balsam pear powder as main raw materials has a significantly better effect on reducing blood sugar than the plant extract in the prior art. Meanwhile, the plant extract composition also has the effects of synergistically reducing the number of peripheral nerve neutrophils, improving peripheral nerve inflammation, synergistically enhancing the fluorescence intensity of peripheral nerves, improving peripheral nerve injury, and inhibiting the enzyme activity of bacteria-derived dipeptidyl peptidase-4.

The invention relates to the field of molecular detection and biological sample treatment, and discloses a saliva collection, pretreatment and cell sorting method for telomere length detection. The method selects saliva as a sample and comprises the following steps: pre-treating the saliva sample; neutrophils in the saliva sample are obtained through magnetic bead sorting, and the obtained neutrophils are used for fluorescent quantitative telomere length detection after being subjected to nucleic acid extraction. According to the method, saliva is selected as a telomere detection sample, no trauma is caused to a human body, and the problems that at present, sample collection is unqualified, transportation is improper, the quality of the saliva sample is unqualified due to long-time placement, follow-up treatment sorting and genome extraction are affected, and correct telomere detection is greatly interfered are effectively solved. Besides, through pretreatment and magnetic bead sorting of a saliva sample, target cells are collected, interference of saliva impurities is reduced, the integrity of the extracted genome DNA is high, the concentration of the target genome is high, subsequent fluorescent quantitative detection is facilitated, and the detection result is more accurate.

The invention discloses an application of Osmunda japonica in relieving fish food-borne intestinal inflammation, regulating intestinal flora and inhibiting bacteria, based on a 9-day soybean meal induced zebra fish enteritis model, 2% o of Osmunda japonica is added, so that aggregation of neutrophils and macrophages in middle and posterior intestines can be relieved, and zebra fish food-borne intestinal inflammation can be relieved; meanwhile, by means of intestinal flora sequencing, it is found that by adding 2% o of rhizoma osmundae, the intestinal flora of the fish with the food-borne intestinal inflammation can be improved; the result of an aeromonas hydrophila in-vitro bacteriostasis experiment shows that the rhizoma osmundae aqueous extract has a remarkable effect of inhibiting aeromonas hydrophila, has an inhibition zone and has a certain bacteriostasis effect, and a zebra fish in-vitro challenge experiment shows that the survival rate of zebra fish can be increased by adding 2 per thousand of rhizoma osmundae.

The invention discloses bifidobacterium adolescentis BAS05 and application thereof in preparation of a medicine for preventing or treating intestinal inflammation, and belongs to the technical field of microorganisms. The preservation number of the bifidobacterium adolescentis BAS05 disclosed by the invention is CGMCC (China General Microbiological Culture Collection Center) No. 22515. The bifidobacterium adolescentis BAS05 can inhibit DSS from inducing neutrophil to gather towards the intestinal tract of the zebra fish, so that a theoretical reference and a guidance basis are provided for developing a medicine for preventing or treating intestinal inflammation by utilizing the bifidobacterium adolescentis BAS05.

The invention relates to the technical field of biological detection, in particular to application of a CCL8 cell factor in a kit for early screening of esophageal cancer, the kit and a prediction method, and the corresponding kit and the prediction method are included. By detecting the content of the CCL8, the correlation between the CCL8 and the morbidity condition of a patient with esophageal squamous carcinoma is disclosed, and a new biomarker is provided for early screening of esophageal carcinoma. Secondly, the CCL8 can recruit immunosuppressive CCR1 + neutrophils, which reveals the immunoregulation mechanism possibly involved in the development process of esophageal cancer, deepens the understanding of the pathogenesis of esophageal cancer, and provides a theoretical basis for the intervention strategy development of CCL8. By detecting the content of CCL8 in serum, early warning of a patient can be realized, and the early diagnosis rate of esophageal cancer is expected to be improved, so that the prognosis of the patient is improved.

A material removes neutrophils while suppressing removal of platelets, the material being a knitted fabric or a woven fabric including a fiber having a fiber diameter of 10 to 60 μm, wherein the knitted fabric or the woven fabric has a thickness of 0.10 to 0.40 mm and a porosity of 10 to 30%.

The invention discloses a hyperlipidemia risk prediction model and a risk prediction system during treatment of TSC by SRL, and belongs to the field of disease model prediction. According to the hyperlipemia risk prediction model disclosed by the invention, three parameters including SRL (Sirolimus) blood drug valley concentration, baseline triglyceride and neutrophil count of an object to be evaluated are input; the output is the risk probability of the to-be-evaluated object suffering from hyperlipemia; large sample data is adopted to train a model, cases suffering from hyperlipemia are positive samples, other cases are negative samples, and the model is selected from XGBoost, a support vector machine, a random forest, a decision tree and LightGBM. The key risk factors of hyperlipemia after SRL treatment are disclosed, accurate prediction of the risk of SRL-related hyperlipemia is achieved, especially the RO-AUC of the XGBoost model reaches 0.95, and the method can be applied to detection instruments, monitoring networks, wearable devices and other scenes.

The application discloses a kind of nanomedicine for treating sepsis and its preparation method and purposes, belong to medical technology field.The nanomedicine is tetrahedral framework nucleic acid modified by N-acetyl proline-glycine-proline.The nanomedicine of the application can be transported to inflammatory site by following the chemotaxis of neutrophil to inflammatory site, to play the target regulation effect on sepsis, to increase the bioavailability of drug, improve the target treatment effect of drug.The nanomedicine of the application can be used not only for preparing the drug for treating sepsis, but also for preparing the drug for treating other diseases caused by neutrophil infiltration, and has wide application prospect.